CRON Stock Analysis: Buy, Sell, or Hold?
CRON - Cronos Group Inc. Common Share
$2.81
-0.02 (-0.71%)
▼
5d:
-1.4%
30d:
+1.81%
90d:
+6.04%
BUY
HIGH Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Smart Money Accumulation
None View Scanner →
Strength: 5.1/10
Get Alerted When CRON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CRON shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CRON shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: CRON is currently trading at $2.81, which is considered fair relative to its 30-day fair value range of $2.75 to $2.84. The stock's valuation (Forward PE: 19.6) is in line with its historical norms (21.1). Remarkably, the market is currently pricing in an annual earnings decline of 2.4% over the next few years. This pessimistic expectation contrasts with the company's recent 126.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CRON is in a strong uptrend. Immediate support is located at $2.70, while resistance sits at $2.91.
Market Sentiment: CRON has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $2.54. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRON is in a strong uptrend. Immediate support is located at $2.70, while resistance sits at $2.91.
Market Sentiment: CRON has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $2.54. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.75 -
$2.84
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
78.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 10.4% above Wall St target ($2.54)
Trading Range Analysis
30-Day Trading Range
$2.75 -
$2.84
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.22
(7.7%)
Support & Resistance Levels
Support Level
$2.70
Resistance Level
$2.91
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.61
Wall Street Target
$2.54
(-10.4%)
Revenue Growth (YoY)
40.1%
Earnings Growth (YoY)
126.8%
Profit Margin
-1.1%
Valuation Discount vs History
-2.4% cheaper
PE vs Historical
19.6 vs 21.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.4%
(market-implied from PE analysis)
1-Year Target
$2.76
(-2%)
2-Year Target
$2.70
(-5%)
3-Year Target
$2.63
(-7%)
3-Yr Target (if PE normalizes)
(PE: 20→21)
$2.83
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 12.0%)
$4.21
(+49%)
Base:
(SPY PE: 19.6, Growth: 12.0%)
$3.98
(+41%)
Bear:
(PE: 16.7, Growth: 12.0%)
$3.38
(+20%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.6 to 21.1
Stabilization Target:
$3.04
(+7.6%)
PE Expansion Potential:
+7.6%
Share & Embed Analysis
Last updated: August 04, 2026 9:50 AM ET
Data refreshes hourly during market hours. Next update: 10:50 AM
Data refreshes hourly during market hours. Next update: 10:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 49 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
Advanced CRON Option Strategies
Professional options setups generated by AI based on today's CRON price and gamma walls.
